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Abstract
Background: Microglial activation, characterized by p38 MAPK or p44/42 MAPK pathway signal transduction, occurs in
Alzheimer’s disease (AD). Our previous studies demonstrated CD45, a membrane-bound protein tyrosine phosphatase (PTP),
opposed b-amyloid (Ab) peptide-induced microglial activation via inhibition of p44/42 MAPK. Additionally we have shown
agonism of the RB isoform of CD45 (CD45RB) abrogates lipopolysaccharide (LPS)-induced microglial activation.
Methodology and Results: In this study, CD45RB modulation of Ab peptide or LPS-activated primary cultured microglial
cells was further investigated. Microglial cells were co-treated with ‘‘aged’’ FITC-Ab1–42 and multiple CD45 isoform agonist
antibodies. Data revealed cross-linking of CD45, particularly the CD45RB isoform, enhances microglial phagocytosis of Ab1–
42 peptide and inhibits LPS-induced activation of p44/42 and p38 pathways. Co-treatment of microglial cells with agonist
CD45 antibodies results in significant inhibition of LPS-induced microglial TNF-a and IL-6 release through p44/42 and/or p38
pathways. Moreover, inhibition of either of these pathways augmented CD45RB cross-linking induced microglial
phagocytosis of Ab1–42 peptide. To investigate the mechanism(s) involved, microglial cells were co-treated with a PTP
inhibitor (potassium bisperoxo [1,10-phenanthroline oxovanadate; Phen]) and Ab1–42 peptides. Data showed synergistic
induction of microglial activation as evidenced by TNF-a and IL-6 release; both of which are demonstrated to be dependent
on increased p44/42 and/or p38 activation. Finally, it was observed that cross-linking of CD45RB in the presence of Ab1–42
peptide, inhibits co-localization of microglial MHC class II and Ab peptide; suggesting CD45 activation inhibits the antigen
presenting phenotype of microglial cells.
Conclusion: In summary, p38 MAPK is another novel signaling pathway, besides p44/42, in which CD45RB cross-linking
negatively regulates microglial Ab phagocytosis while increasing potentially neurotoxic inflammation. Therefore, agonism of
CD45RB PTP activity may be an effective therapeutic target for novel agents to treat AD due to its Ab lowering, and
inflammation reducing, properties that are particularly targeted at microglial cells. Such treatments may be more effective
with less potential to produce systemic side-effects than therapeutics which induce non-specific, systemic down-regulation
of inflammation.
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Introduction
Classic findings of AD on autopsy are senile plaques,
neurofibrillary tangles, cerebral amyloid angiopathy, neuronal
loss, neuronal cytoskeleton disruption with altered connectivity,
and widespread synaptic loss. Although the precise etiology of AD
remains uncertain, it may result from an elevation in brain b-
amyloid (Ab) protein[1]. Indeed, Ab peptide generation and
aggregation as plaques are key pathological events in the
development of AD [2,3]. They have been extensively studied
and evidenced to be neurotoxic, as they are reported mediators of
inflammation [4,5].
Activated microglia also play a critical role in the inflammatory
processes of AD, as they secrete cytokines in response to Ab,
including tumor necrosis factor a (TNF-a) and interleukin-1 b (IL-
1b) which promote neurodegeneration [6,7]. However, current
anti-inflammatory therapeutics directed against AD, including
nonsteroidal anti-inflammatory drugs (NSAIDs), only partially
suppress microglial activation [8,9]. Furthermore to date, random-
ized, double-blind clinical trials of NSAIDS in AD patients have
been negative [10], one trial on secondary prevention has not been
promising, and there have been no prevention trials completed.
Thus, a more viable therapeutic strategy may be combination of
NSAIDs with specific inhibitors of microglial activation [11].
One viable target on microglia is the CD40-CD40L signaling
pathway. This pathway is involved in both T-cell and microglial
cell activation [12–15]. We demonstrated ligation of microglial
CD40 synergistically enhanced autocrine activation by Ab peptide
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2135[13]. As such, this pathway can be effectively used as a target for
opposing both T-cell [15] and microglial activation.
To explore the possibility of immunomodulating CD40 activity,
we showed that CD45, a protein tyrosine phosphatase (PTP),
activation inhibits CD40L-induced microglial activation via down-
regulation of the p44/42 mitogen activated protein kinase
(MAPK) pathway [14]. Indeed, a synergistic induction of
microglial TNF-a and nitric oxide (NO) release was found to be
dependent on activation of p44/42 MAPK. Further, co-treatment
with a PTP inhibitor [potassium bisperoxo (1,10-phenanthroline
oxovanadate; phen)] and Ab peptides resulted in microglia-
induced neuronal injury. Conversely, stimulation of microglial
CD45 by CD45 antibody markedly inhibited these effects via
inhibition of p44/42 MAPK, suggesting CD45 is a negative
regulator of microglial activation. Accordingly, primary cultured
microglia from CD45-deficient mice displayed hyper-responsive-
ness to Ab, as evidenced by TNF-a release, NO production, and
neuronal injury. In vivo, brains from a transgenic mouse model of
AD [Swedish APP-overexpressing (Tg2576) mice] deficient for
CD45 further confirmed increased production of TNF-a com-
pared with Tg2576 mice [11].
CD45 is a haemopoietic cell specific PTP, essential for antigen
receptor-mediated signaling in T and B cells [16], as well as
microglia [17,18]. It modulates signaling through cytokine
receptors as well as cellular adhesion [19–21]. The CD45 protein
is encoded by a single gene (PTPRC; protein tyrosine phosphatase,
receptor-type C) and different isoforms can be cleaved by
alternative splicing of three variable exons: A, B, and C [22].
Expression of the various isoforms is tightly regulated by cell type
and state of activation. In humans, naive/unprimed T cells express
high molecular weight isoforms containing exon A, however upon
activation CD45RB is the predominant form[11,23]. CD45 may
be particularly salient to the clinical features of AD since microglia
express it in the frontal cortex and hippocampus of normal aging
individuals. This expression level is markedly elevated in these
brain regions in AD cases [24]. Furthermore, in an animal model
of neurodegeneration, upregulation of PTP signaling in activated
microglia was found in and around degenerating brain regions
[25]. As phosphorylation of the related cytoplasmic serine
threonine kinase, p38 MAPK, is also a response to Ab and
inflammatory molecules, it is likely that p38 MAPK activation is
also critical to the disease cascade. Indeed activation of the p38
pathway in microglia or neurons may stimulate the production of
inflammatory mediators, thereby contributing to the degeneration
or further activation of these cells. Together these data led us to
investigate the possible involvement of CD45RB PTP signaling as
a putative down-regulator of microglial p38 activation in response
to Ab peptides.
Results
The cross-linking of CD45RB enhances microglial
phagocytosis of Ab1–42 peptide
Microglial phagocytosis of Ab is most likely a terminal event
leading to removal of b-amyloid from the brain parenchyma [26].
In our recent studies we identified that CD45 cross-linking opposes
both Ab and CD40L-stimulated microglial activation [14,27].
Thus to examine the functionality of CD45 isoforms, we first
evaluated whether cross-linking with CD45 specific agonist
antibodies (CD45RA, CD45RB and CD45RC antibodies) could
modulate microglial uptake of Ab. ‘‘Aged’’ FITC-tagged Ab1–42
(500 nM) was added to primary cultured microglial cells for 2 h in
the absence (control), presence of either variant CD45 specific
antibodies [CD45 (total), CD45RA, CD45RB, CD45RC], or IgG
isotype-control (2.5 mg/mL). As a control for non-phagocytic
incorporation of Ab by microglia, microglial cells were incubated
at 4uC in parallel cell culture plates under the same treatment
conditions described above. Cell supernatants and lysates were
analyzed for extracellular and cell-associated FITC-Ab using a
fluorometer. As shown in Fig. 1A (top and bottom panel), the
cross-linking of CD45, mainly isoform CD45RB, enhances
microglia phagocytosis of Ab1–42 peptide. This enhancement of
Ab1–42 phagocytosis peptides was verified by quantitative
immunofluorescence assay (Fig. 1B). In a parallel experiment,
results further showed microglial phagocytosis of Ab1–42 peptide
was localized within the cytoplasm of microglial cells (Fig. 1C).
LPS-mediated microglial p38 and p44/42 MAPK
activation hinders microglial phagocytosis of Ab1–42
peptide
It has been reported that the MAPK pathway is central to the
biological activities of LPS [28]. This was evidenced by a rapid
and transient increase in phosphorylation of both p38 and p44/42
in LPS-stimulated microglial cells. We treated microglial cells with
SB203580 (SB, 5 mM; an inhibitor of p38 MAPK) or PD98059
(PD, 5 mM; a selective inhibitor of p44/42) for 1 h prior to
treatment with LPS (100 ng/mL) for 30 minutes, and found both
inhibitors markedly suppressed the activation of LPS-induced p38
or p44/42 MAPKs (Fig. 2A, B). To investigate whether p38
MAPK and/or p44/42 MAPK are involved in microglial
phagocytosis of Ab1–42 peptide, microglial cells were further pre-
treated with either of these inhibitors for 1 h, then co-treated with
‘‘aged’’ FITC-tagged Ab1–42 (500 nM) in complete medium for
2 h in the absence (control) or presence of LPS (100 ng/mL). As
shown in Fig. 2C (top and bottom panels), both of SB203580 and
PD98059 significantly increased microglial phagocytosis of Ab1–42
peptide, with SB230580 showing a more potent effect, a
phenomenon which was reversible by LPS stimulation. Together
these data indicate p38 MAPK and/or p44/42 MAPK is involved
in negative regulation of microglial phagocytosis of Ab1–42 peptide.
Cross-linking of CD45RB inhibits LPS induced activation
of p38 pathway as well as microglial activation
These observations promoted us to investigate the effect of
cross-linking CD45RB on LPS-induced p38 MAPK activity in
microglial cells. Therefore to determine the signaling mechanism
of CD45RB, p38 MAPK phosphorylation was evaluated by
Western blot analyses. As shown in Fig. 2D, treatment with LPS
(10 ng/mL) for 30 minutes induced significant p38 MAPK
phosphorylation. This effect was markedly suppressed by
CD45RB antibody (2.5 mg/mL), suggesting that cross-linking
CD45RB may attenuate activation of p38 MAPK induced by
LPS. We have previously shown that cross-linking of CD45 using
an agonistic CD45 antibody leads to inhibition of microglial
activation induced by Ab/CD40 ligation and LPS, as evidenced
by TNF-a release and bystander neuronal cell injury [13,14].
Together with this previous data, it seems that CD45 signaling
down-regulates microglial pro-inflammatory responses to LPS
challenges. To further investigate whether CD45RB signaling-
associated cytokines could be involved in modulating microglial
phagocytosis by inhibiting p38 MAPK activity, we examined the
effect of cross-linking of CD45RB on the production of TNF-a
and IL-6 by measuring their concentrations in culture media
supernatant. This effect was mimicked by SB203580. It was shown
in Fig. 2E (top and bottom panels) that application of CD45RB
antibody (2.5 mg/mL) or SB203580 (5 mM) significantly inhibited
LPS-induced TNF-a and IL-6 secretion, and co-treatment with
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PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2135Figure 1. The cross-linking of CD45RB enhances microglia phagocytosis of Ab1–42 peptide. (A) Cell supernatants and lysates were
analyzed for extracellular (top panel) and cell-associated (bottom panel) FITC-Ab1–42 using a fluorometer. Data are represented as the relative fold of
mean fluorescence change (mean6SD), calculated as the mean fluorescence for each sample at 37uC divided by mean fluorescence at 4uC (n=6 for
each condition presented). One-way ANOVA followed by post-hoc comparison showed a significant between-group difference (*P,0.05, **P,0.001
compared with control or isotype-control IgG). (B) Subsequently, fluorescence microscope examination was performed using a 406objective with
appropriate filter selection. The dark field images (panels a, c and e) show the fluorescence of FITC labeled Ab1–42 and DAPI-labeled nuclear stain,
whereas, b, d and f show only the FITC Ab1–42 stain of the same fields. (C) In parallel experiments, microglial cells were treated with 1 mM ‘‘aged’’ FITC-
Ab1–42 and CD45RB antibody for 2 h. Following treatment, these cells were fixed and stained with DAPI. The images were analyzed by confocal
microscope and show FITC-Ab1–42 (green staining) localized within the cytoplasm of microglia cells.
doi:10.1371/journal.pone.0002135.g001
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PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2135Figure 2. Activated p38 MAPK and/or p44/42 MAPK by LPS negatively affects microglial phagocytosis of Ab1–42 peptide. Microglial
treatment conditions are indicated and are further described in Materials and Method. Cell lysates were analyzed by Western immunoblotting using
specific antibodies that recognize phosphorylated or total p38 MAPK and/or p44/42 MAPK at the indicated time points (A and B, top panel).
Phosphorylation of both p38 MAPK and/or p44/42 MAPK after treatment with LPS was inhibited by SB203580 or PD98059 (A and B, bottom panel).
Histograms below the immunoblots represent the mean band density ratio61 SD (pp38 MAPK/total p38 MAPK and/or pp44/42 MAPK/total p44/42
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of TNF-a and IL-6 secretion. These data suggest that activation of
p38 MAPK is crucial for microglial TNF-a and IL-6 production
after challenging LPS, and demonstrate the functionality of
CD45RB cross-linking on p38 MAPK activity.
Inhibition of both p38 and/or p44/42 pathways further
enhanced cross-linking CD45RB mediated microglial
phagocytosis of Ab peptide
Our previous studies have shown either SB203580 or PD98059
inhibitor markedly attenuate CD40 signaling-stimulated activation
of p38 or p44/42 MAPK in microglial cells [13,29]. To determine
the role of the p38 and/or p44/42 MAPK cascades in the
CD45RB signaling-mediated microglial phagocytosis of Ab
peptide, microglial cells were pre-treated with SB203580 (5 mM)
or PD98059 (5 mM) for 1 h, then co-treated with ‘‘aged’’ FITC-
tagged Ab1–42 (500 nM) for 2 h in the absence (control) or
presence of CD45RB antibody or isotype control IgG. Cell culture
supernatants were collected and cell lysates were prepared to
measure Ab by fluorometer (Fig. 3A). In parallel experiments,
microglial cells were treated as above. Cell lysates were then
prepared and assessed by Ab ELISA (Fig. 3B for SB203580 and
Fig. 3C for PD98059). These data collectively showed that cross-
linking CD45RB boosts microglial phagocytosis of Ab peptide,
which was enhanced by inhibition of p38 or p44/42 activities.
Cross-linking of microglial CD45RB markedly suppresses
p38 MAPK activation resulting from phen and Ab peptide
co-treatment
It has been reported that a tyrosine phosphorylation cascade
plays an important role in Ab-induced microglial activation
[30,31]. Our previous studies demonstrated phen (a specific
tyrosine phosphatase inhibitor) synergistically enhanced Ab-
stimulated microglial activation [27]. CD45, a protein-tyrosine
phosphatase that is constitutively expressed on microglia [25], is
markedly increased on microglia from AD frontal cortices [24,32].
To investigate the role of CD45RB in microglial activation, we
treated primary cultured microglial cells with monoclonal
CD45RB antibody before stimulation with phen and Ab peptide.
Microglial activation, as evidenced by TNF-a and IL-6 release
after co-treatment of microglia with phen and Ab peptide, was
significantly inhibited by cross-linking CD45RB (Fig. 4A, top and
bottom panels). Our previous studies have confirmed this result in
vivo [11].
Previous studies have shown that activation of p44/42 MAPK is
involved in TNF-a production in macrophages, monocytes, and
microglia after activation with a variety of stimuli, including LPS
and CD40 ligand [13,33,34]. Further our previous studies
demonstrated fresh Ab peptides activate p44/42 MAPK in
microglial cells only when CD45 receptor is inactivated with
tyrosine phosphatase inhibitors [27]. These data led us to further
investigate whether the observed effect of CD45 cross-linking on
opposing microglial activation might be mediated via activation of
the p38 MAPK modulation. First, we analyzed p38 MAPK
phosphorylation status. As shown in Fig. 4B, the p38 MAPK
pathway was rapid and transiently activated by fresh Ab. Second,
we analyzed activated p38 MAPK status in microglial cell lysates
after co-treatment with phen, Ab, CD45RB antibody or
SB203580. Results showed p38 MAPK phosphorylation was
inducedwithin30 minutes after co-treatment with phen and Ab1–42
peptide, which was abrogated by cross-linking of CD45RB or
SB203580, respectively (Fig. 4C, D). Furthermore, to determine
whether activation of p38 MAPK was responsible for TNF-a and
IL-6 production after co-treatment of microglia with phen and Ab
peptide, we treated microglial cells with SB203580 or PD 98059
and CD45RB antibody before stimulation with phen and Ab
peptide. Production of TNF-a and IL-6 were markedly decreased
compared with appropriate controls within 16 h after treatment as
above (Fig. 4E, top and bottom panels). These data suggest
activation of p38 MAPK is crucial for microglial TNF-a and IL-6
production following co-treatment with phen and Ab peptide, and
also suggest cross-linking of CD45RB synergizes with SB203580 to
inhibit phen and Ab-induced activation. In addition, we also
observed that cross-linkingofCD45RB has the same synergistic role
with PD98059 in inhibiting phen and Ab peptide-induced
microglial activation (data not shown).
Cross-linking of CD45RB inhibits co-localization of
microglial MHC class II and Ab peptide
MHC class II plays an important role in loading and
transporting extracellular pathogens and toxin to the APC surface,
where they are recognized by CD
+ T cells [35]. This cell surface
protein is particularly interesting, as microglial cells express it in
the frontal cortex and hippocampus of normally aging individuals
and levels of expression are markedly increased in these brain
regions in AD cases [36,37]. The impairment of MHC II function
results in a significant reduction of microglia-associated CNS
inflammation [37,38], suggesting the elevated level of MHC class
II expression is strongly associated with a microglial immune
response. Recently, we have shown that CD40 ligation increases
MHC II-Ab peptide complexes as examined by fluorescence
microscopy [5]. In addition, we previously showed cross-linking of
CD45 significantly opposes CD40-mediated microglial activation
[14]. To examine whether cross-linking of CD45RB could inhibit
formation of immunogenic MHC II-Ab peptide complexes on the
cell surface, we treated microglia with CD45RB antibody (2.5 mg/
mL) in the presence or absence of ‘‘aged’’ Cy3-Ab1–42 peptide
(300 nM) for 48 h, followed by immunofluorescence staining with
FITC-conjugated anti-mouse MHC class II antibody. Result show
that cross-linking of CD45RB inhibits MHC class II-Ab co-
localization as detected by fluorescence microscopy (Fig. 5).
Discussion
Microglial activation has the potential to be pathogenic in an
array of neurodegenerative diseases including multiple sclerosis
[39], HIV associated dementia [40], and AD [41,42]. In the case
of AD however, these cells may be therapeutic in clearing brain
deposits of aggregated Ab peptide if induction of a phagocytic state
MAPK; n=3 for each condition presented; *P,0.05, **P,0.001 compared with control). (C) Microglial phagocytosis of Ab1–42 peptide after pre-
treatment with PD98059 or SB203580 for 1 h, then co-treated with ‘‘aged’’ FITC-tagged Ab1–42 and LPS. Supernatants and cell lysates were analyzed
for extracellular (top panel) and cell-associated (bottom panel) FITC-Ab1–42 using a fluorometer (*P,0.05, **P,0.001). (D) Phosphorylation of p38
MAPK and inhibition of this effect by CD45RB antibody. Histograms below the immunoblots represent the mean band density ratio61 SD (pp38/total
p38; n=3 for each condition presented; *P,0.05 compared with LPS or LPS/IgG). (E) Microglial activation is evidenced by mean TNF-a and IL-6
release61 SD (n=3 for each condition presented; *P,0.05; **P,0.001 compared with LPS or LPS/IgG; P,0.05 compared LPS/SB with LPS/CD45RB
Ab/SB). For A–E, one-way ANOVA followed by post hoc Bonferroni testing was utilized. Note: SB=SB203580, PD=PD98059, Ab=antibody,
pp=phosphorylatioin.
doi:10.1371/journal.pone.0002135.g002
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neuroinflammation mediated via microglial activation have only
been partially efficacious, possibly because of the fact that such
strategies are general inhibitors of inflammation rather specific
modulators of the inflammatory versus phagocytic phenotypes of
microglia. For example postmortem brain tissue from AD patients
who underwent NSAID treatment and control individuals who did
not use NSAIDs [43] revealed no significant differences in the
mean numbers of senile plaques, senile plaque subtypes (diffuse or
neuritic), or neurofibrillary pathology between cases and controls.
However the numbers of activated microglia were significantly
decreased in NSAID-treated AD patients compared with controls.
These data suggest NSAIDs may be therapeutic for AD partially
due to their opposition of microglial inflammatory activation.
Thus pharmacotherapeutics specifically aimed at blocking mi-
croglial inflammatory activation, while promoting microglial Ab
phagocytosis, may hold significant potential for the treatment of
Ab-associated neuropathology in AD. Accumulating evidence has
revealed that microglial ‘‘activation’’ is not simply one phenotypic
manifestation. The modern view of activated microglia classifies
them into two main categories: a phagocytic phenotype (innate
activation) or an antigen presenting phenotype (adaptive activa-
tion), as governed by their stimulatory environment. Additionally,
when challenged with certain pathogen-associated molecular
patterns (PAMPs), particularly CpG-DNA, murine microglia seem
to activate a ‘‘mixed’’ response characterized by enhanced
phagocytosis and pro-inflammatory cytokine production as well
as adaptive activation of T cells [44]. Various models of
neurodegenerative demonstrate these states of microglial activa-
tion whose effects are detectable in human post-mortem brain
samples. For example, experimental autoimmune encephalitis
model seems to largely support an adaptive, antigen presenting
activation of encephalitogenic T cells in the presence of the CD40-
CD40 ligand interaction [45–47]. Likewise in HIV associated
dementia models demonstrate a strong Th1 profile in the CNS
[48]. In the context of Ab challenge in the PSAPP mouse model of
AD, CD40 ligation is able to shift activated microglia from innate
to adaptive activation. Further, it seems that the cytokine milieu
that microglia are exposed to biases these cells to innate activation
(i.e., anti-inflammatory Th2-associated cytokines such as IL-4, IL-
10, and perhaps TGF-b1) or an adaptive form of activation (i.e.,
pro-inflammatory Th1-associated cytokines such as IFN-c, IL-6,
and TNF-a) (for review see [49]). Not all forms of microglial
activation are deleterious, as activated microglia may serve a
protective role as was shown in Ab1–42-immunized mouse models
of AD [26,50,51]. It seems that enhanced microglial phagocytosis
of b-amyloid plaques is at least partly responsible for the
therapeutic benefit in these animals, so perhaps stimulation of
innate microglial activation contributes to these reported benefits.
In this study, we focused on identifying the signaling
mechanisms involved in CD45RB agonism of microglial Ab
phagocytic phenotype. Our rationale for such investigation is
based on our previous works in which we have shown the
microglial antigen presenting cell (APC)-like phenotype is
characterized by pro-inflammatory cytokine secretion, deficient
amyloid clearance, and high levels of MHC II expression [5,11].
This is crucial because when the APC-like phenotype is inhibited,
by CD40 neutralizing antibody or pharmacotherapeutics such as
statins, microglia reduce their expression of pro-inflammatory
neurotoxic cytokines and efficiently phagocytize Ab from the
brain, resulting in accompanying cognitive improvement in mouse
models of the disease [11,12,14,52]. Our data show that cross
linking of CD45RB enhances microglial phagocytosis of Ab1–42
peptide while suppressing potentially neurotoxic microglia medi-
ated inflammation. This is exemplified by the fact that co-
treatment with the PTP inhibitor phen and Ab peptides resulted in
microglial activation as evidenced by increased TNF-a and IL-6
secretion.
p38 is a mitogen-activated protein kinase (MAPK) involved in
apoptosis, inflammation and responses to environmental stress
[53]. We previously showed that p44/42 inhibition by CD45
agonism is possible [11], and that activation of either p38 or p42/
44 pathways leads to a pro-inflammatory microglial phenotype
with poor phagocytic ability [5]. Here, we further show that the
p44/42 and p38 pathways confer a significant reduction in
microglial Ab phagocytosis and that pre-treatment with selective
inhibitors of either p44/42 or p38 significantly upregulates
microglial clearance of Ab peptide (Fig. 2C). We suggest
antagonism of p38 by CD45RB stimulation leads to significant
reductions in phospho-p38 as shown in figure 2D. However this
antagonism of p38 by CD45RB stimulation is likely several folds
lower in magnitude than that conferred by the specific p38
inhibitor, SB. Thus the antagonistic effects of CD45RB stimula-
tion on p38 may be undetectable secondary to the very strong p38
antagonism already provided by SB. This may underlie the lack of
an additive or synergistic suppression of IL-6 and TNF-a response
between the LPS/SB versus LPS/CD45RB Ab/SB groups.
Nevertheless, these finding supports a strong positive correlation
between inhibition of proinflammatory microglial activation and
Ab phagocytosis as is evident in the significant increase in cell
associated Ab in the SB condition compared to control (Fig. 2C).
Furthermore, it was also revealed that p38 MAPK activation is
more heavily involved in inhibition of microglial phagocytosis of
Ab1–42 peptide than p44/42 (Fig. 2C), which is in agreement with
previous studies indicating the central role of p38 in response to
inflammatory CNS stimuli [13,33,34,53].
Our previous findings indicated that CD45 inhibits microglial
TNF-a release induced by Ab/CD40 ligation and LPS, [12,13,27]
as well the reduced microglial phagocytosis under CD45RB
suppression. Here, we further show the relative involvement of p38
and p44/42 signaling in CD45RB signal transduction. Specifical-
ly, cross-linking of CD45RB in microglia was partially mediated
by inhibition of both p38 and p44/42 MAPK activities and hence
inversely associated with Ab phagocytosis. The inhibition of these
MAPKs and enhanced Ab phagocytosis was also supported by an
overall shift in microglial phenotype from a pro-inflammatory
APC-like state, to an Ab-clearing phagocytic state as was evident
by reduction of MHC class II-Ab co-localization following the
CD45RB cross-linking. MHC class II plays an important role in
transport extracellular pathogens and toxin to the APC surface,
Figure 3. Inhibition of both p38 and/or p44/42 pathways further enhances CD45RB cross-linking mediated microglial phagocytosis
of Ab1–42 peptide. Microglial treatment conditions are indicated and are further described in Material and Methods. (A) Cell supernatants and
lysates were analyzed for extracellular (top panel) and cell-associated (bottom panel) FITC-Ab1–42 using a fluorometer. Data are represented as the
relative fold of mean fluorescence change (mean6SD), calculated as the mean fluorescence for each sample at 37uC divided by mean fluorescence at
4uC (n=6 for each condition presented). Cell lysates (B, C) were assayed for microglial phagocytosis of Ab1–42 peptide by Ab-ELISA. Results are
reported as picogram per microgram of total protein for cells incubated at 37uC over cells incubated at 4uC. (37uC/4uC; n=3 for each condition
presented). One-way ANOVA followed by post hoc Bonferroni testing revealed significant between-group differences (*P,0.05, **P,0.001) and
CD45RB Ab compared with isotype-control IgG, P,0.001. Note: SB=SB203580, PD=PD98059, Ab=antibody, pp=phosphorylatioin.
doi:10.1371/journal.pone.0002135.g003
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by CD+ T cells. Microglia express it in the frontal cortex and
hippocampus of normally aging individuals. Levels of expression
are markedly increased in these brain regions in AD cases [36,37].
Impairment of MHC class II function has previously been shown
to induce significant reduction of microglia-associated CNS
inflammation (including MS and AD) [37,38]. An elevated level
of MHC class II expression is strongly associated with a pro-
inflammatory, non-phagocytic microglia immune response. For
example we have shown CD40 ligation results increased MHC
class II loaded Ab peptide complexes associated with reduced
amyloid clearance and a neurotoxic elevation of CNS pro-
inflammatory cytokines [5].
In summary the AD brain is plagued by a complex
inflammatory process, involving neurons and astrocytes, in
addition to microglia. It has been suggested the interaction of
activated astrocytes and microglia together with the neurons
stressed by Ab peptides sensitize microglia to extracellular stimuli,
which then activate MAPK pathways and neurotoxic cytokine
release. Indeed transgenic mice overexpressing human amyloid
precursor protein (APP) develop early AD-like changes, including
diffuse, extracellular Ab deposits in the brain, and specific spatial
learning and pneumonic deficits [54–57]. In addition, these
animals demonstrate approximately threefold elevation in the
number of activated p38 MAPK-positive cells in the brain [58].
More importantly this activity is very specific to microglia with no
colocalization with neuronal or astrocytic markers. Indeed many in
vitro studies have shown fibrillar Ab peptides induce rapid
activation of both p38 and p44/42 MAPKs, resulting in increased
TNF-a and NO release [30,31,59,60], while we have shown fresh
Ab peptides activate p44/42 MAPK in microglia only when CD45
receptor is inactivated by PTP [14].
Taken together these data raise the possibility that stimulation
of the CD45RB pathway negatively controls microglial activation
induced by various proinflammatory stimuli through suppression
of both p38 and p42/44 MAPK intracellular signaling systems.
Conversely we found CD45RB pathway stimulation positively
regulates amyloid clearance suggesting that pharmacotherapeutics
targeting stimulation of this receptor may be beneficial in
suppressing microglial inflammatory activation and enhancing
Ab clearance; biological correlates which hold strong potential to
ameliorate the symptoms of AD.
Materials and Methods
Materials
Mouse anti-human Ab monoclonal antibody (BAM-10) was
purchased from Sigma (St. Louis, MO). Ab1–42 and FITC-
conjugated Ab1–42 were obtained from Biosource International
(Camarillo, CA). Orange fluorescing cyanine dye, Cy3, was
purchased from Amersham (Piscataway, NJ) for conjugation with
Figure 4. Cross-linking of CD45RB markedly inhibits phen and Ab peptide-induced microglial activation. (A) Microglial cells were
treated as indicated for 16 h. Microglial activation was determined by TNF-a and IL-6 production (mean61 SD, picograms per milligram of total
protein) in cultured media (top and bottom panels). Data are representative of three independent experiments (**P,0.001). (B–D) Cell lysates were
analyzed by Western immunoblotting using specific antibodies that recognize phosphorylated p38 MAPK at the indicated time points.
Phosphorylation of p38 MAPK is indicated in (B) and inhibition of this effect by CD45RB Ab is indicated in Fig C or by SB in Fig. D. Histograms below
the immunoblots represent the mean band density ratio61 SD (p38/total p38 MAPK; n=3 for each condition presented). (E) Microglial cells were pre-
treated with SB230580 or CD45RB antibody for 1 h, then co-treated with phen and/or aged Ab1–42 for 16 h. Microglial activation was determined by
TNF-a and IL-6 production (mean61 SD) in cultured media (top and bottom panels; n=3 for each condition presented). One-way ANOVA followed by
post hoc Bonferroni testing revealed significant differences (*P,0.05, ** P,0.001). Note: SB=SB203580, Ab=antibody, pp=phosphorylation).
doi:10.1371/journal.pone.0002135.g004
Figure 5. Cross-linking of CD45RB inhibits microglia MHC class II-Ab co-localization. In order to examine microglia MHC II-Ab peptide
complex formation on the cell surface, microglia were treated with ‘‘aged’’ Cy3-Ab1–42 peptide (300 nM) in the presence or absence of agonist
CD45RB antibody for 48 h followed by staining with FITC-anti-mouse MHC class II antibody and Fluorescence microscopy. Note: Red indicates Ab-
positive; green indicates MHC class II-positive; yellow indicates the co-localization of MHC class II and Ab, Ab indicates antibody. Blue indicates DAPI
nuclear stain of the same fields. Original magnification=406for top and bottom panels.
doi:10.1371/journal.pone.0002135.g005
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including anti-CD45RB, anti-CD45RC, anti-CD45RA, and
purified rat IgG2b control antibodies) and purified FITC-anti-
mouse MHC class II antibodies were obtained from PharMingen
(San Diego, CA). DuoSet
TM mouse TNF-a ELISA kit was
obtained from R&D systems (Minneapolis, MN). Mouse IL-6
ELISA kit was obtained from eBioscience (San Diego, CA).
Antibodies for phospho-p44/42 (pp44/42, Thr202/Tyr204)
MAPK, phospho-p38 (pp38, Thr180/Tyr182) MAPK, total
p44/42 MAPK, and total p38 MAPK were obtained from Cell
Signaling Technology (Beverly, MA) as well as cell lysis buffer, and
SDS blue loading buffers. PD98059 (a specific MEK1/2 inhibitor),
SB203580 (a specific p38 MAPK inhibitor), and bisperoxo (1, 10-
phenanthroline) oxovanadate (phen) were obtained from Calbio-
chem (La Jolla, CA).
Each of these was dissolved in DMSO before adding to
complete cell medium. DMSO alone was used as a solvent control,
which did not differ from the untreated controls presented.
Bacterial lipopolysaccharide (LPS) was obtained from Sigma (St.
Louis, MO) and dissolved in complete cell culture medium. Anti-
mouse and anti-rabbit HRP-conjugated IgG secondary antibodies
and Western blotting luminol reagent were obtained from Pierce
(Rockford, IL). Immun-Blot polyvinylidene difluoride (PVDF)
membranes were purchased from Bio-Rad systems (Minneapolis,
MN). Anti-Ab1–17 monoclonal antibody (6E10) and biotinylated
anti-Ab17–24 monoclonal antibody (4G8) were obtained from
Signet Laboratories (Dedham, MA).
Murine primary cell culture
Breeding pairs of BALB/c mice (Jackson Laboratory, Bar
Harbor, ME) were housed in the animal facility at the University
of South Florida Health Science Center. Murine primary culture
microglia were isolated from mouse cerebral cortices and grown in
complete RPMI 1640 medium according to previously described
methods [27]. Briefly, cerebral cortices from newborn mice (1–
2 days old) were isolated under sterile conditions and kept at 4uC
prior to mechanical dissociation. Cells were grown in RPMI 1640
medium supplemented with 5% heat-inactivated FCS, 2 mM
glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and
50 mM 2-mercaptoethanol. Primary cultures were kept for 14 days
so that only glial cells remained. Microglial cells were isolated by
shaking flasks at 200 rpm in a Lab-Line
TM Incubator-Shaker.
More than 98% of these glial cells stained positive for Mac-1
(Boehringer Mannheim, Indianapolis, IN).
Microglial phagocytosis assays
Primary mouse microglia were seeded at 1610
5 cells/well (n=6
for each condition) in 24-well tissue culture plates containing
0.5 mL of complete RPMI 1640 medium. These cells were treated
for 2 h with ‘‘aged’’ Ab1–42 conjugated with FITC (Biosource
International; 500 nM pre-aggregated for 24 h at 37uCi n
complete medium as described by [61]). In the presence of
FITC-Ab1–42, microglial cells were then co-treated with agonist
CD45, CD45RB, CD45RC, and CD45RA antibodies, or isotype
control IgG (2.5 mg/mL). Some of these cells were treated with
PD98059 (5 mM) or SB203580 (5 mM) for 1 h prior to LPS
(100 ng/mL), or CD45RB antibody (2.5 mg/mL), isotype control
IgG (2.5 mg/mL) or BAM-10 (2.5 mg/mL), in the presence of
FITC-Ab1–42 for 2 h. Microglial cells were then rinsed three times
in Ab-free complete medium, and the media were exchanged with
fresh Ab-free complete medium for 10 minutes to allow for
removal of non-incorporated Ab and promote concentration of
Ab into phagosomes. Extracellular and cell-associated FITC-Ab
were quantified using an MSF (SpectraMaxH, Molecular Devices)
with an emission wavelength of 538 nm and an excitation
wavelength of 485 nm. A standard curve from 0 to 600 nM of
FITC-Ab was run for each plate. Total cellular proteins were
quantified using the Micro BCA Protein Assay (Pierce, Rockford,
IL). The mean fluorescence values for each sample at 37uC and
4uC at the 2 h point were determined by fluorometric analysis.
Relative fold change values were calculated as: mean fluorescence
value for each sample at 37uC/mean fluorescence value for each
sample at 4uC. In this manner, both extracellular and cell-
associated FITC-Ab were quantified. Considering nonspecific
adherence of Ab to the plastic surface of culture plates, an
additional control without cells was carried out through all of
experiments above. An incubation time of less than 4 h did not
change the amount of Ab peptide detected in the supernatant,
which is consistent with a previous report [62]. In order to
determine the extent to which cell death might have influenced the
phagocytic activity in the various treatment groups, we performed
the LDH assay on the relevant supernatant. Data showed that
there was no significant cell death occurring over the 3 h time
frame in any of the treatment groups (data not shown, P,0.05).
Fluorescence microscope examination
‘‘Aged’’ FITC-Ab1–42 was prepared according to methods
described above. Microglial cells were cultured at 1610
5 cells/well
in 24-well tissue culture plates with glass inserts. In the presence of
FITC-Ab1–42 (1 mM), microglial cells were co-treated with agonist
CD45RB antibody (2.5 mg/mL) or isotype control IgG (2.5 mg/
mL) at 37uC for 2 h. Additionally, in parallel 24-well tissue culture
plates, microglial cells were incubated at 4uC with the same
treatment as above. Following treatment, these cells were washed
five times with ice-cold phosphate buffered saline (PBS) to remove
extracellular Ab and fixed for 10 minutes at 4uC in 4% (w/v)
paraformaldehyde (PFA) diluted in PBS, followed by staining with
49,6-Diamidino-2-Phenylindole (DAPI) at 4uC for 15 minutes.
Finally sections were mounted with fluorescence mounting media
containing Slow Fade antifading reagent (molecular Probes,
Eugene, OR), and then viewed under an Olympus IX71/IX51
microscope equipped with a digital camera system (406). Cy3-
Ab1–42 was prepared according to previous methods [61]. Primary
microglial cells (seeded in 24-well tissue culture plates at 5610
4
cells/well) were treated with Cy3-Ab1–42 peptide (300 nM) in the
presence or absence of agonist CD45RB antibody at 37uC for
48 h. Following treatment, these cells were washed, fixed, and
permeabilized in 0.2% triton X-100, 5% horse serum for 1 h. This
was followed by staining with FITC-anti-mouse MHC class II
antibody (2 mg/mL incubated overnight at 4uC). Slides were
analyzed using the same microscope equipped as above.
Fluorescence confocal microscopy
In parallel with the Fluorescence microscope examination, slides
were viewed with a Leica DMI6000 inverted microscope, TCS SP5
confocal scanner, and 636/1.4NA Plan Apochromat oil immersion
objectives (Leica Microsystems, Germany). Excitation wavelengths
of 488 nm (for FITC) and 405 nm (for DAPI) were used to generate
fluorescence emission in green (for Ab1–42) and blue (for nuclei),
respectively. Images were captured with photomultiplier detectors
at 36zoom and were prepared with the LAS AF software version
1.6.0 build 1016 (Leica Microsystems, Germany). DIC image were
also captured using the 488 laser line.
TNF-a, IL-6, and Ab ELISA
TNF-a and IL-6 ELISA. Primary cultured microglial cells
were plated in 24-well tissue culture plates (Costar, Cambridge,
MA) at 5610
4 cells/well for 24 h. They were then stimulated for
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LPS (10 ng/mL) in the presence or absence of pretreatment (1 h)
with agonist CD45RB antibody (2.5 mg/mL), PD98059 (5 mM),
SB203580 (5 mM), or appropriate controls. Cell-free supernatants
were collected and assayed by TNF-a (Minneapolis, MN), and IL-
6 (San Diego, CA) ELISA kits in strict accordance with the
manufacturer’s instruction. The BCA Protein Assay (Pierce,
Rockford, IL) was performed to measure total cellular protein
from each of the cell groups under consideration just before
quantification of cytokine release.
Ab ELISA. Primary mouse microglial cells were seeded at
1610
5 cells/well (n=6 for each condition) in 24-well tissue culture
plates containing 0.5 mL of complete RPMI 1640 medium. These
cells were incubated at 37uC and 4uC with the same treatment
conditions as microglial phagocytosis assays. Cell lysates were
prepared and quantization of microglial phagocytosis of total Ab
peptides was performed according to published methods [63].
Briefly, 6E10 (capture antibody) was coated at 2 mg/mL in PBS in
96-well immunoassay plates overnight at 4uC. The plates were
then washed with 0.05% Tween-20 in PBS five times and blocked
with blocking buffer (PBS with 1% bovine serum albumin, 5%
horse serum) for 2 h at room temperature. Conditioned medium
or Ab standards were added to the plates and incubated overnight
at 4uC. Following three washes, biotinylated antibody 4G8
(0.5 mg/mL in PBS with 1% bovine serum albumin) was added
to the plates and incubated for 2 h at room temperature. After five
washes, streptavidin-horseradish peroxidase (1:200 dilutions in
PBS with 1% bovine serum albumin) was added to the 96-well
plates for 30 minutes at room temperature. Tetramethylbenzidine
substrate was then added to the plates and incubated for
15 minutes at room temperature. Then 50 mL of stop solution (2
NH 2SO4) was added to each well of the plates. The optical density
of each well was immediately determined by a microplate reader
at 450 nm. In addition, Ab1–42 was quantified in these samples
using the Ab1–42 ELISA kits (IBL-America, Minneapolis, MN) in
accordance with the manufacturer’s instructions.
Western immunoblotting
Murine primary culture microglia were plated in six-well tissue
culture plates at a density of 8610
5 cells/well. These cells were
incubated for 30 minutes with or without LPS (10 ng/mL), Ab1–42
(1 mM), phen (5 mM)+Ab1–42 (1 mM), in the presence or absence of
pretreatment (1 h) with CD45RB antibody, isotype control IgG
(2.5 mg/mL), PD98059 (5 mM), SB203580 (5 mM), or appropriate
controls. After treatment, microglial cells were washed in ice-cold
PBS three times. Next the cells were lysed with 16 SDS sample
buffer [62.5 mM Tris-HCI (pH6.8), 2% SDS, 10% glycerol,
50 mM dithiothreitol], sonicated for 15 seconds, and then heated
to 100uC for 5 minutes. The cell lysates were centrifuged at
12,000 rpm (4uC) for 5 minutes, and the protein concentration of
the supernatant was measured by BCA Protein Assay System
(Pierce). Western blotting of phosphorylated p38 or p44/42
MAPK was performed according to the manufacturer’s instruc-
tions using phospho-specific antibodies. Briefly, proteins were
electrophoresed on a 10% SDS-PAGE gels and transferred to
immunoblotting PVDF membranes (Bio-Rad). The membranes
were blocked for 1 h at room temperature in Tris-buffered saline
(TBS, Bio-Red), 0.1% Tween-20 with 5% nonfat dry milk, and
then were incubated with primary antibodies overnight at 4uC.
After incubation with horseradish peroxidase-conjugated second-
ary antibody, the protein bands were detected with a Super Signal
west Femto Maximum Sensitivity Substrate (Pierce) and BIO-
MAX-MR film (Eastman Kodak Co.). For detection of total p38
and p44/42, the membranes were stripped with Restore Western
blot Stripping Buffer (Pierce) followed by incubation with specific
antibodies.
Statistical analysis
All experiments were performed at least three times, and the
representative results were shown. Data were analyzed using
ANOVA followed by post hoc comparisons of means by
Bonferroni’s. A value of P,0.05 was considered statistically
significant.
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